Skip Nav Destination
Issues
1 February 2010
-
Cover Image
Cover Image
Colocalization of uPAR and α3 integrin with phospho-ERK staining in murine oral squamous cell carcinoma of the tongue (OSCC). Complex formation between uPAR and α3β1 integrin activates an ERK-dependent signal transduction pathway resulting in transcriptional regulation in OSCC cells. Tongue tumors formed following injection of cells exhibiting uPARα3β1 integrin interaction are poorly differentiated, aggressive, infiltrative lesions with perineural and vascular invasion. Using four-color immunofluorescence, colocalization of uPAR and α3 integrin is evident in murine OSCC tumors also exhibiting ERK phosphorylation, supporting the hypothesis that uPARα3β1 integrin association regulates ERK-dependent gene expression in vivo. Phospho-ERK (green), uPAR (red), α3 integrin (magenta), DAPI (blue). For further details, please see Ghosh and coworkers on page 145 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Angiogenesis, Metastasis, and the Cellular Microenvironment
Cancer Genes and Genomics
DNA Damage and Cellular Stress Responses
FEN1 Functions in Long Patch Base Excision Repair Under Conditions of Oxidative Stress in Vertebrate Cells
Kenjiro Asagoshi; Keizo Tano; Paul D. Chastain, II; Noritaka Adachi; Eiichiro Sonoda; Koji Kikuchi; Hideki Koyama; Kenji Nagata; David G. Kaufman; Shunichi Takeda; Samuel H. Wilson; Masami Watanabe; James A. Swenberg; Jun Nakamura
Signaling and Regulation
Letters to the Editor
Highlights
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.